Keywords: add-on, benefits, actos, shown, study, eli, lilly/takeda
Add-on benefits of Actos shown in study
Article | 20 June 2005
Eli Lilly/Takeda Pharmaceuticals' Actos (pioglizatone HCl) has been shown to reduce C-reactive protein and interleukin-6, both markers of inflammation ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
